MenaQ7® Clinical Studies: What Does the Human Research Show?

Key takeaways:

• Strongest evidence: MK-7 increases circulating vitamin K and improves activation of vitamin K-dependent proteins such as osteocalcin and MGP.
• Bone health: Some long-term studies report improvements in bone-related measures, but results are mixed. Fracture prevention has not been established.
• Vascular health: Clinical trials report improvements in arterial stiffness measures such as cfPWV, but this does not prove prevention of heart attacks or strokes.
• Coronary calcification: A 2026 trial found a smaller increase in coronary artery calcium with MK-7, but the clinical significance remains uncertain.
• Absorption: MK-7 is absorbed and remains measurable in circulation for an extended period.
• Safety: Studies in healthy adults generally show good short-term tolerability at studied doses.
• Drug interaction: MK-7 can interfere with vitamin K antagonist anticoagulants such as warfarin and acenocoumarol.
• Evidence limitation: Research on generic MK-7 or other vitamin K2 forms should not automatically be treated as evidence specifically for MenaQ7®.
  
  

MenaQ7® clinical studies have investigated menaquinone-7 (MK-7), a form of vitamin K2, across vitamin K status, bone health, vascular function, absorption, and safety.

The most consistent research shows that MK-7 increases vitamin K status and improves the activation of vitamin K-dependent proteins such as osteocalcin and matrix Gla protein (MGP). Clinical trials have also examined bone-related measures, arterial stiffness, vascular function, and other physiological outcomes.

The key is to look at what each study actually measured. Improvements in vitamin K biomarkers or vascular measurements provide evidence of biological activity, but they do not automatically establish prevention of cardiovascular disease, osteoporosis, or fractures.

What Does the Research Show About MenaQ7®?

Human clinical research involving MenaQ7® MK-7 has primarily investigated:

• Vitamin K status and protein activation

• Bone mineral density and bone-related measures

• Arterial stiffness and vascular function

• MK-7 absorption and pharmacokinetics

• Safety and interaction with vitamin K antagonist anticoagulants
  
  

Across these areas, the strongest and most consistent evidence concerns vitamin K status and activation of vitamin K-dependent proteins.

Importantly, not every study of MK-7 used the MenaQ7® branded ingredient. When interpreting the evidence, the specific MK-7 source, dose, population, study design, and outcome should be considered.

MenaQ7® Clinical Research at a Glance

The studies differ in design, population, duration, and endpoints, so their findings should not be treated as interchangeable.

What Does MenaQ7® Do in the Body?

MenaQ7® provides menaquinone-7 (MK-7), a long-chain form of vitamin K2.

Vitamin K is required for the carboxylation and activation of vitamin K-dependent proteins. Two proteins frequently examined in MK-7 research are:

• Osteocalcin (OC), associated with bone metabolism

• Matrix Gla protein (MGP), involved in vascular tissue biology
  
  

Researchers can measure inactive forms such as:

• Undercarboxylated osteocalcin (ucOC)

• Dephosphorylated-uncarboxylated MGP (dp-ucMGP)
  
  

When these inactive forms decrease, it indicates greater vitamin K-dependent protein activation.

This provides a direct way to measure whether MK-7 is biologically active in humans.

Does MenaQ7® Improve Vitamin K Status?

Yes. This is one of the clearest findings from human MK-7 research.

In a 12-week randomized clinical study, 60 healthy men and postmenopausal women consumed yogurt providing approximately 56 μg/day of MK-7.

Circulating MK-7 increased from approximately 0.28 ng/mL to 1.94 ng/mL. The study also reported reductions in ucOC and dp-ucMGP, indicating increased activation of vitamin K-dependent proteins.

Another randomized study examined different MK-7 preparations and found that daily supplementation increased vitamin K activity, including greater osteocalcin carboxylation.

What does this mean?

These studies provide direct human evidence that MK-7 is absorbed, increases circulating vitamin K status, and activates vitamin K-dependent proteins.

That is currently the clearest foundation for understanding the biological effects of MenaQ7® and MK-7 supplementation.

What Does MenaQ7® Research Show About Bone Health?

MenaQ7® has been studied in relation to several bone-related outcomes.

A three-year randomized, placebo-controlled study followed 240 healthy postmenopausal women receiving 180 μg/day of MenaQ7® MK-7 or placebo.

The MenaQ7® group showed substantial improvement in vitamin K-dependent osteocalcin activation. The study also reported statistically significant improvements in selected measures of bone mineral content, bone mineral density, and bone strength.

The three-year duration makes this study particularly relevant because many supplement trials are considerably shorter.

However, the wider MK-7 literature is not uniformly positive. For example, another three-year randomized trial in 142 postmenopausal women with osteopenia used 375 μg/day of MK-7 alongside calcium and vitamin D. It improved osteocalcin carboxylation but did not produce a significant difference in bone mineral density or microarchitecture compared with placebo.

What does this mean?

The human evidence supports a clear effect of MK-7 on vitamin K-dependent bone markers. Evidence for improvements in bone structure and density is more mixed and appears to depend on the study population, dose, and study design.

The research therefore supports MenaQ7® as a clinically studied form of MK-7 for bone-related outcomes, but it does not establish fracture prevention or treatment of osteoporosis.

Can MenaQ7® Affect Arterial Stiffness?

Yes. Several human studies have investigated MK-7 and measurable vascular characteristics.

In a three-year double-blind, placebo-controlled trial, 244 healthy postmenopausal women received 180 μg/day of MenaQ7® MK-7 or placebo.

The study reported significant reductions in carotid-femoral pulse wave velocity (cfPWV) and other measures of arterial stiffness. Improvements in several local arterial measures were particularly apparent among women who had higher arterial stiffness at baseline. MK-7 also reduced dp-ucMGP by approximately 50% compared with placebo.

A separate one-year randomized study included 243 adults aged 40–70 with low vitamin K status. Participants received 180 μg/day of MenaQ7® MK-7 or placebo.

The study reported significant reductions in both dp-ucMGP and cfPWV.

What does cfPWV tell us?

Carotid-femoral pulse wave velocity is a recognized measure of arterial stiffness and is widely used in vascular research.

A reduction in cfPWV demonstrates a change in a measurable vascular characteristic. It does not, by itself, demonstrate fewer heart attacks, strokes, or cardiovascular deaths.

The clinical evidence therefore supports an effect of MK-7 on vascular measurements, while cardiovascular disease prevention remains a separate question.

What Does Newer Research Show About Coronary Calcification?

More recent research has begun examining harder vascular outcomes.

A 2026 randomized clinical trial included 180 patients with symptomatic coronary artery disease and existing coronary artery calcification. Participants received 360 μg/day of MK-7 or placebo for two years.

MK-7 supplementation significantly increased circulating MK-7 levels. Coronary artery calcium scores increased in both groups, but the increase was smaller in the MK-7 group, with a statistically significant between-group difference. The study also reported a similar finding for calcium mass. No significant adverse effects were observed.

The authors concluded that MK-7 may slow calcification in noncalcified plaques, while noting that the clinical significance of this finding for plaque stability remains to be determined.

This is an important addition to the human evidence, but it is still an imaging outcome rather than proof that MK-7 prevents heart attacks, strokes, or other cardiovascular events.

How Well Is MenaQ7® Absorbed?

Human pharmacokinetic research shows that MK-7 is absorbed after oral supplementation and can remain measurable in circulation for an extended period.

Studies have examined different MK-7 doses and formulations and consistently demonstrate measurable circulating MK-7 after supplementation. Research using a single 1 mg dose found peak plasma concentrations at approximately six hours and a relatively long half-life.

This pharmacokinetic profile helps explain why MK-7 is suitable for once-daily supplementation and why relatively modest doses can produce sustained circulating levels.

The exact pharmacokinetic response can vary with dose, formulation, food intake, and individual characteristics.

What Does MenaQ7® Research Show About Safety?

Clinical research in healthy adults generally indicates that MK-7 is well tolerated at the doses studied.

A dose-response study involving 42 healthy adults compared daily MK-7 doses ranging from 10 to 360 μg for three months. MK-7 increased the carboxylation of vitamin K-dependent proteins without producing adverse effects on thrombin generation.

Another study involving 40 healthy adults receiving 90 μg/day of MK-7 for 30 days found no significant changes in measured coagulation parameters.

These findings support a favorable short-term safety profile in healthy people.

Does MenaQ7® interact with blood-thinning medication?

Yes. This is an important exception to the generally favorable safety findings.

Vitamin K can interfere with vitamin K antagonist anticoagulants.

In a clinical study involving 18 people receiving acenocoumarol, participants were given 10, 20, or 45 μg/day of MK-7. Even the 10 μg/day dose affected anticoagulation sensitivity in some participants.

Anyone taking a vitamin K antagonist such as warfarin or acenocoumarol should therefore discuss MK-7 supplementation with their prescribing clinician or anticoagulation specialist.

Is MenaQ7® Research the Same as Research on All Vitamin K2?

No.

MenaQ7® provides MK-7, while vitamin K2 is a broader category that includes other menaquinones such as MK-4.

These forms differ in their chemical structure, pharmacokinetics, and studied doses. Research on MK-4 should therefore not automatically be presented as evidence for MenaQ7® MK-7.

For an ingredient-specific clinical evidence article, studies using MenaQ7® MK-7 are the most directly relevant evidence, while broader MK-7 research can provide supporting context when the specific ingredient source is different.

How Strong Is the Evidence for MenaQ7®?

The evidence varies depending on what outcome is being considered.

The strongest evidence therefore concerns what MK-7 does biologically in the body: increasing vitamin K status and activating vitamin K-dependent proteins.

Bone and vascular research provides additional clinical evidence, but those findings should be interpreted according to the specific population, endpoint, dose, and study design.

What Doses of MenaQ7® Have Been Studied?

Human research has investigated MenaQ7® MK-7 across a broad dose range.

These are research doses, not universal dosage recommendations. Dose selection depends on the specific product, intended use, dietary vitamin K intake, and individual circumstances.

Frequently Asked Questions

What is MenaQ7®?

MenaQ7® is a branded source of menaquinone-7 (MK-7), a form of vitamin K2 studied in human clinical research.

What is the strongest evidence for MenaQ7®?

The strongest human evidence shows that MK-7 increases vitamin K status and improves activation of vitamin K-dependent proteins such as osteocalcin and matrix Gla protein.

Does MenaQ7® support bone health?

Human studies have reported improvements in vitamin K-dependent bone markers and, in some studies, bone mineral density and bone-strength measures. However, results across MK-7 trials are not completely consistent, and fracture prevention has not been established.

Does MenaQ7® affect arterial stiffness?

Several clinical studies have reported favorable changes in measures such as cfPWV and arterial elasticity following MK-7 supplementation.

How much MenaQ7® has been studied?

Human studies have investigated MK-7 doses ranging from nutritional amounts such as 56–90 μg/day to 180–360 μg/day and higher doses in specific research settings.

Is MenaQ7® safe?

Clinical studies in healthy adults generally indicate that MK-7 is well tolerated over the study periods examined. However, vitamin K can interact with vitamin K antagonist anticoagulants.

Final Thoughts

MenaQ7® has a substantial body of human clinical research supporting its role as a clinically studied source of MK-7. The research consistently shows that MK-7 increases vitamin K status and improves the activation of vitamin K-dependent proteins, with clinical studies also reporting meaningful changes in bone-related measures and vascular function.

Overall, MenaQ7® clinical research demonstrates measurable biological and physiological effects in humans, particularly at studied doses used across nutritional, bone, and vascular research. The evidence provides a strong scientific basis for understanding MenaQ7® as a well-researched form of vitamin K2, while continued research will further define its effects on long-term health outcomes.

At Just Glow, we believe science-backed ingredients and evidence-based nutrition are the foundation of long-term wellness. Our carefully selected supplements are designed to complement a balanced diet and healthy lifestyle.